INTRIVO DIAGNOSTICS SECURES NATIONAL DISTRIBUTION AGREEMENT WITH MCKESSON MEDICAL-SURGICAL FOR ACCESS BIO CARESTART™ COVID-19 TESTS
In accordance with Article 16 (1) of the “Korean Depository Receipt Agreement” signed between Access Bio and Korea Securities Depository on March 11, 2013, the Record Date for determining shareholders in 2020 is December 31, 2020.
Major supply chain agreements will ensure broad access to rapid testing solutions for patients and healthcare providers across US
Emergency Use Authorization Granted for CareStartTM Point-Of-Care Kit
Global Leader in Infectious Disease Diagnosis Receives FDA EUA for Serology Test Capable of Determining Subjects’ past COVID-19 Exposure and Immunoresponse within 10 Minutes
Global Leader in Infectious Disease Diagnosis Receives FDA EUA for Molecular Test that May Provide Laboratories Results in 83 Minutes or Less
Access Bio was founded on the basic principle of cherishing life and health for all people. The company has emerged as a leader in the diagnosis of infectious diseases. Although it provides a comprehensive portfolio, Access Bio is known for its work against malaria, HIV, HPV, and now, COVID-19.
Malaria and its effects are primarily concentrated in poor, developing nations. in 2018, there were an estimated 228 million cases around the world and more than 400,000 deaths. Of those, more than 90% of cases and mortalities occurred in the sub-Saharan region of Africa, and children under the age of 5 account for two-thirds of all malaria deaths worldwide.
New rapid diagnostic test now available to research organizations for low parasitemia settings